- Home
- AEMD vs XRTX Comparison
AEMD vs XRTX Comparison
Compare AEMD & XRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AEMD | XRTX |
|---|---|---|
| Founded | 1984 | 2011 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Pharmaceuticals and Biotechnology |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6M | 4.3M |
| IPO Year | 2008 | 2018 |
Fundamental Metrics
Financial Performance| Metric | AEMD | XRTX |
|---|---|---|
| Price | $2.24 | $2.80 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $15.00 | N/A |
| AVG Volume (30 Days) | 23.9K | ★ 1.8M |
| Earning Date | 02-12-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.31 | $0.35 |
| 52 Week High | $5.89 | $3.60 |
Technical Indicators
Market Signals| Indicator | AEMD | XRTX |
|---|---|---|
| Relative Strength Index (RSI) | 47.77 | 56.05 |
| Support Level | $2.18 | $0.44 |
| Resistance Level | $2.46 | $3.00 |
| Average True Range (ATR) | 0.11 | 0.25 |
| MACD | -0.01 | -0.10 |
| Stochastic Oscillator | 25.00 | 9.86 |
Price Performance
Historical ComparisonAbout AEMD Aethlon Medical Inc.
Aethlon Medical Inc is a medical therapeutic company. The company is focused on addressing unmet needs in health and biodefense. The company is focused on the development of Hemopurifier, a clinical-stage therapeutic device designed to combat cancer and eliminate life-threatening viruses from the circulatory system.
About XRTX XORTX Therapeutics Inc.
XORTX Therapeutics Inc is a clinical-stage pharmaceutical company focused on developing therapies to treat gout and progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications such as allopurinol-intolerant gout and autosomal dominant polycystic kidney disease, as well as more prevalent type 2 diabetic nephropathy and fatty liver disease. Its focus is on developing products to slow and/or reverse the progression of these diseases. The Company operates in one reportable operating segment: the development and commercialization of therapies to treat hyperuricemia-related diseases.